Richard Scott Struthers - 14 Aug 2023 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
14 Aug 2023
Transactions value $
$19,100
Form type
4
Filing time
16 Aug 2023, 17:30:15 UTC
Previous filing
13 Jul 2023
Next filing
06 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $19.1K +10K +7.97% $1.91* 136K 14 Aug 2023 Direct
holding CRNX Common Stock 631K 14 Aug 2023 By Family Trust 1
holding CRNX Common Stock 1K 14 Aug 2023 By Spouse
holding CRNX Common Stock 90K 14 Aug 2023 By Family Trust 2
holding CRNX Common Stock 90K 14 Aug 2023 By Family Trust 3
holding CRNX Common Stock 90K 14 Aug 2023 By Family Trust 4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Incentve stock option (Right to Buy) Options Exercise $0 -10K -6.2% $0.00 151K 14 Aug 2023 Common Stock 10K $1.91 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.